Positive Topline Results Announced from Ph 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and PFS in RRMM Patients September 9, 2026
Imfinzi + Imdelltra demonstrated statistically significant OS & PFS improvement in 1L ES-SCLC September 9, 2026
Positive Topline Results Announced from Registrational Ph 2 QUINTESSENTIAL Trial of GPRC5D-Directed CAR T Cell Therapy Arlocabtagene Autoleucel September 9, 2026
Positive Outcome Announced from First Planned Interim Efficacy Analysis from FORTE Basket Study of Plixorafenib Monotherapy in Advanced Solid Tumors with BRAF Fusions September 9, 2026
100% Three-Year DFS announced with TG4050 and Ph 1 Results Published in Nature Communications September 9, 2026
NEJM Publishes Ph 1/2 Clinical Data on RASONQUE™ (daraxonrasib) in Metastatic NSCLC September 9, 2026
Ivonescimab Meets OS Key Secondary Endpoint in Interim Analysis of Ph 3 HARMONi-2 Study, Demonstrating Statistically Significant Benefit Versus Pembrolizumab in 1L PD-L1-Positive NSCLC September 9, 2026
SANOVO Trial Demonstrated Significant PFS Benefit of ORPATHYS + TAGRISSO in 1L Patients with MET-Overexpressing EGFR-mutated Lung Cancer in China September 2, 2026
Ziihera® (zanidatamab-hrii) + Chemo Demonstrates Statistically Significant OS Benefit vs Trastuzumab + Chemo in 1L HER2+ Advanced GEA September 2, 2026
Confirmed Durable Partial Response Achieved in Ph 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy September 2, 2026
Ivonescimab + Chemo Global Ph 3 HARMONi Primary Analysis Results Published in The Lancet Oncology September 2, 2026
Updated NEST Ph 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer September 2, 2026
Ivonescimab + Chemo Demonstrates Statistically Significant OS Benefit vs Durvalumab + Chemo in 1L Advanced BTC in China September 2, 2026
Ph 3 INTerpath-001 Trial of Intismeran Autogene + KEYTRUDA Met RFS and DMFS Endpoints in Patients With Completely Resected Stage IIB-IV Melanoma August 25, 2026
Zipalertinib + Chemo Meet Primary PFS Endpoint in Planned Interim Analysis of Ph 3 REZILIENT3 Trial in 1L EGFR Exon 20 Insertion Mutation NSCLC August 20, 2026
Enhertu demonstrated statistically significant and clinically meaningful PFS improvement in HER2-mutant NSCLC in DESTINY-Lung04 Ph 3 trial August 20, 2026
Final ASTRUM-002 Analysis Shows Survival Benefit with Hetronifly in Advanced non squamous NSCLC After Four Years of Follow-Up August 20, 2026
FAILED TRIAL: Ph 2 DeFianCe study of sirexatamab (DKN-01) in 2L CRC did not meet primary endpoint of PFS improvement August 20, 2026
Positive Topline Ph 2a Results for Intranasal NEO100 in Recurrent IDH1-Mutant High-Grade Glioma Reported August 20, 2026
ORPATHYS + TAGRISSO Demonstrated Statistically Significant PFS/OS Improvements in MET-Driven EGFR-Mutated Lung Cancer After Progression on TAGRISSO August 20, 2026
Topline Results from Intranasal NEO100 in Recurrent IDH1-mutant High-grade Glioma to be presented August 11, 2026
FAILED TRIAL: Ph 3 XPORT-EC-042 Trial of Selinexor in Endometrial Cancer Did Not Meet the Primary Endpoint of PFS improvement August 5, 2026
MIRACLE R/R AML Trial Reports Positive Interim Data with 37% Blinded CRc in Venetoclax-Failed Patients August 5, 2026
Positive Updated Ph 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma Announced July 28, 2026
